Company: TELO
Filing Date: 2025-11-20
Form Type: 8-K
Source: 0001493152-25-024450
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

The
findings expand Telomir-1’s oncology profile into cancers of the blood, adding to previously reported activity in triple-negative
breast, pancreatic, and aggressive prostate cancer models.

Telomir
Pharmaceuticals, Inc. (NASDAQ:TELO) (“ Telomir” or the “ Company”), a preclinical-stage biotechnology company developing
small-molecule therapies targeting the epigenetic and metabolic roots of cancer, aging, and age-related disease, today announced new
in vitro findings showing that its investigational compound Telomir-1 kills aggressive human leukemia (HL60) cells.

Study
Summary

Human
HL60 leukemia cells were exposed to Telomir-1 across a range of concentrations. Telomir-1 produced a clear, dose-dependent reduction
in leukemia cell viability

Iron
Dependence and Epigenetic Silencing in Leukemia

Leukemia
is a cancer of the blood and bone marrow marked by uncontrolled growth of abnormal white blood cells. Scientific literature describes
how leukemia cells depend heavily on intracellular iron

Iron
also serves as a required cofactor for several epigenetic enzymes silencing tumor-suppressor genes

Relevance
to Prior Telomir-1 Research

Although
the leukemia study measured cell viability only, earlier Telomir-1 research provides important biological context:

Intracellular
Iron Modulation

In
prior live-cell imaging studies using human cell systems, Telomir-1 produced a marked, concentration-dependent reduction of intracellular
Fe²⁺ significantly greater intracellular iron-lowering activity than Deferoxamine
(DFO) at the same concentrations

DFO
is known to act primarily in the bloodstream and extracellular space and has limited ability to penetrate living cells intracellular

Because
leukemia cells rely heavily on elevated intracellular iron to fuel DNA replication, mitochondrial activity, and iron-dependent epigenetic
enzymes, the ability of a compound to modulate iron inside the cell

Epigenetic
Regulation

In
earlier cancer research, Telomir-1 reduced abnormal DNA methylation of several tumor-suppressor genes - including STAT1, CDKN2A,
MASPIN, RASSF1A, CASP8 GSTP1

Several
of these regulatory mechanisms are described in the scientific literature as highly